February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Lt ...

February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Lt ...

Core Viewpoint - Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer and Company Secretary, promoting her to the Board of Directors, effective immediately [2][4]. Group 1: Leadership Changes - Fiona Sharp has been with Biodexa since December 2019, initially serving as Group Financial Controller, and has expanded her responsibilities to include many CFO duties [3]. - Stephen Stamp will step down from his roles as CFO and Company Secretary but will continue as Chief Executive Officer [4]. Group 2: Company Background - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [5]. - The company's lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [5]. Group 3: Product Development - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor that plays a significant role in cellular metabolism and tumorigenesis [6]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential as a first-in-class blood glucose modulating agent [6]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier to reduce systemic toxicity [7]. Group 4: Company Capabilities - Biodexa is supported by three proprietary drug delivery technologies aimed at enhancing the bio-delivery and bio-distribution of medicines [8].

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].

Registration No. 333-291598 As filed with the U.S. Securities and Exchange Commission on December 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Em ...

As filed with the U.S. Securities and Exchange Commission on December 11, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Em ...

As filed with the U.S. Securities and Exchange Commission on December 8, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Emp ...

Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on December 8, 2025. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Emp ...

Core Viewpoint - Biodexa Pharmaceuticals has initiated the enrollment of the first three patients in Europe for its pivotal Phase 3 Serenta trial of eRapa, targeting familial adenomatous polyposis (FAP), a hereditary condition that significantly increases the risk of colorectal cancer if untreated [2][4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including eRapa for FAP and other products for various conditions [2][9]. Trial Details - The Serenta trial (NCT06950385) is a double-blind, placebo-controlled study involving 168 patients, with a randomization ratio of 2:1 for drug versus placebo, aimed at evaluating the safety and efficacy of eRapa in FAP patients [4]. - The trial has identified all study sites and is onboarding additional European sites in the Netherlands, Spain, Denmark, and Italy, with nine more expected to activate in the next 2-3 months [4]. - The trial is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas [4]. Disease Context - Familial adenomatous polyposis (FAP) is a rare inherited disorder leading to the development of numerous colorectal polyps and a near-100% lifetime risk of colorectal cancer if untreated, with a prevalence of 1 in 5,000 to 10,000 in the US and 1 in 11,300 to 37,600 in Europe [5]. - Current treatment options for FAP are limited, primarily involving surgical resection, highlighting the need for effective and less invasive therapies [5]. Product Information - eRapa is an oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor, designed to improve bioavailability and reduce toxicity compared to existing rapamycin formulations [6][10]. - The rationale for using eRapa in FAP treatment is supported by the over-expression of mTOR in FAP polyps, indicating its potential effectiveness [6]. Funding and Support - The Cancer Prevention and Research Institute of Texas has awarded $2.9 billion in grants to support cancer research, with a total investment of $6 billion approved by Texas voters for cancer research and prevention [7].

Core Insights - Biodexa Pharmaceuticals has activated its first European site for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP), marking a significant milestone in expanding treatment options for European patients [1][2] Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, including eRapa for FAP and other therapies for type 1 diabetes and rare brain cancers [7] Clinical Trial Details - The Serenta trial is a randomized, double-blind, placebo-controlled study designed to assess the efficacy of eRapa in preventing disease progression in FAP patients, who face a near-100% risk of colorectal cancer by age 50 if untreated [3][4] - The trial began enrolling patients in the US in August 2025, with nine additional European sites expected to activate in the next 2-3 months across the Netherlands, Spain, Denmark, and Italy [3] Treatment Context - FAP is a rare inherited disorder characterized by the development of numerous colorectal polyps, leading to a significant unmet need for effective, less invasive therapies, as current standard care involves surgical resection [4] - eRapa, a proprietary oral formulation of rapamycin, is an mTOR inhibitor that targets the over-expression of mTOR in FAP polyps, providing a rationale for its use in treatment [5][8] Funding and Support - The advancement of the Serenta trial has been supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, alongside collaborations with Emtora Biosciences and Precision for Medicine [2][6]